Why the study?
Does intravenous verapamil improve conversion to sinus rhythm in patients with sustained supraventricular tachycardia?
Does intravenous verapamil improve conversion to sinus rhythm in patients with sustained supraventricular tachycardia?
Intravenous verapamil is highly effective for terminating re-entrant supraventricular tachycardias, primarily through its depressive action on the AV node.
Answers are grounded in this paper and cite their sources.
Supports first-line IV verapamil for acute SVT termination; confirms high efficacy versus placebo in re-entrant tachycardias.
We evaluated efficacy and mechanisms of the antiarrhythmic action of verapamil in 20 patients with sustained supraventricular tachycardia. Two patients had sinus nodal re-entrant tachycardia, nine atrioventricular (AV) nodal re-entrant tachycardia, and nine AV reciprocating tachycardia associated with the Wolff-Parkinson-White syndrome. The study design comprised a double-blind, randomized, cross-over phase using a 0.075 mg/kg dose of verapamil versus placebo and an open-label phase using a 0.15 mg/kg dose of verapamil. The overall results of both phases showed that 15 of 19 patients converted to sinus rhythm with verapamil while only one of 16 converted to sinus rhythm with placebo. The effective plasma verapamil concentration measured 123 +/- 40 ng/mL (mean +/- SD). Verapamil suppressed sinus nodal and AV nodal re-entry but exerted no selective depression between fast and slow AV nodal pathways. It had no significant effect on accessory AV bypass tract but was effective in terminating AV reciprocating tachycardia by its depressive action on the AV node.
No takes yet. Share an insight, caveat, or question.
Ruey J. Sung (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: